Kyverna Therapeutics (NASDAQ:KYTX) Price Target Lowered to $6.00 at HC Wainwright

Kyverna Therapeutics (NASDAQ:KYTX) had its target price dropped by HC Wainwright from $7.00 to $6.00 in a report issued on Wednesday,Benzinga reports. The firm currently has a “neutral” rating on the stock. HC Wainwright’s price target suggests a potential upside of 47.06% from the company’s previous close.

KYTX has been the topic of a number of other research reports. Rodman & Renshaw began coverage on Kyverna Therapeutics in a report on Wednesday, October 9th. They set a “buy” rating and a $16.00 price target on the stock. UBS Group initiated coverage on Kyverna Therapeutics in a research note on Thursday, October 10th. They issued a “buy” rating and a $13.00 target price on the stock. JPMorgan Chase & Co. cut their price target on Kyverna Therapeutics from $39.00 to $33.00 and set an “overweight” rating for the company in a research note on Wednesday, July 31st. RODMAN&RENSHAW upgraded shares of Kyverna Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 9th. Finally, Wells Fargo & Company cut their price objective on shares of Kyverna Therapeutics from $44.00 to $24.00 and set an “overweight” rating for the company in a research report on Friday, November 15th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $25.71.

Kyverna Therapeutics Trading Down 7.4 %

Shares of NASDAQ KYTX opened at $4.08 on Wednesday. Kyverna Therapeutics has a twelve month low of $3.94 and a twelve month high of $35.06. The stock has a 50 day moving average of $5.40 and a two-hundred day moving average of $8.34.

Kyverna Therapeutics (NASDAQ:KYTX) last issued its quarterly earnings results on Wednesday, November 13th. The company reported ($0.80) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.01. The business had revenue of $0.01 million for the quarter. On average, equities research analysts forecast that Kyverna Therapeutics will post -3.31 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD acquired a new stake in shares of Kyverna Therapeutics in the 1st quarter worth approximately $23,093,000. Novo Holdings A S boosted its position in Kyverna Therapeutics by 150.0% during the second quarter. Novo Holdings A S now owns 1,750,000 shares of the company’s stock worth $13,125,000 after purchasing an additional 1,050,000 shares in the last quarter. E Fund Management Co. Ltd. acquired a new stake in Kyverna Therapeutics in the second quarter valued at $1,421,000. Great Point Partners LLC increased its position in shares of Kyverna Therapeutics by 232.8% in the second quarter. Great Point Partners LLC now owns 499,152 shares of the company’s stock valued at $3,744,000 after buying an additional 349,152 shares in the last quarter. Finally, Janus Henderson Group PLC acquired a new position in shares of Kyverna Therapeutics during the 1st quarter worth $15,041,000. 18.08% of the stock is owned by hedge funds and other institutional investors.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.